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Bacterial neonatal meningitis results in high mortality and morbidity rates for those affected. Although 
improvements in diagnosis and treatment have led to a decline in mortality rates, morbidity rates 
have remained relatively unchanged. Bacterial resistance to antibiotics in this clinical setting further 
underlines the need for developing other technologies, such as phage therapy. We exploited an in 
vitro phage therapy model for studying bacterial neonatal meningitis based on Escherichia coli (E. 
coli) EV36, bacteriophage (phage) K1F and human cerebral microvascular endothelial cells (hCMECs). 
We show that phage K1F is phagocytosed and degraded by constitutive- and PAMP-dependent LC3-
assisted phagocytosis and does not induce expression of inflammatory cytokines TNFα, IL-6, IL-8 or 
ifnβ. Additionally, we observed that phage K1F temporarily decreases the barrier resistance of hCMEC 
cultures, a property that influences the barrier permeability, which could facilitate the transition 
of immune cells across the endothelial vessel in vivo. Collectively, we demonstrate that phage K1F 
can infect intracellular E. coli EV36 within hCMECs without themselves eliciting an inflammatory or 
defensive response. This study illustrates the potential of phage therapy targeting infections such as 
bacterial neonatal meningitis and is an important step for the continued development of phage therapy 
targeting antibiotic-resistant bacterial infections generally.
Bacterial meningitis is characterised by severe inflammation of the meninges, a network of connective tissues 
surrounding the brain and spinal cord. The inflammation is a result of bacterial invasion into the subarachnoid 
space, between the arachnoid and pia mater and can be caused by numerous bacterial species with meningococci, 
pneumococci, Group B streptococci and Escherichia coli being the most prevailing species1,2. These acute and 
potentially life-threatening infections require rapid diagnosis and initiation of treatment, usually administration 
of antibiotics and sometimes corticosteroids. The disease is more common in neonates and young children as 
their immune systems are relatively immature, with incidence rates of 1/5,000 in full-term neonates and 1/500 in 
low-birth-weight neonates in developed countries. The mortality rate for treated bacterial neonatal meningitis 
is reported at 5–20%, with significant life-changing neurological sequelae for 25–50% of survivors that include 
cognitive impairment, deafness, blindness and seizures3,4. E. coli strains are a prevalent cause of bacterial neonatal 
meningitis5, in particular, strains that express the K1 capsule6, an α-2,8-linked polysialic acid polymer, that covers 
the surface of the bacteria thus hiding many of its antigenic features. This capsule is believed to enhance its ability 
to evade the human immune system and to traverse the blood-brain-barrier (BBB)5,6, highlighting the clinical 
importance of this particular pathogen as a therapeutic target.
Improvements in diagnosis and treatment of bacterial neonatal meningitis have seen a gradual decline in mor-
tality rates in recent decades, while long term post-infection morbidity rates have remained relatively unchanged3. 
However, the emergence of antibiotic resistance is a major cause of concern and could lead to a resurgence in 
mortality rates; this is supported by recent epidemiological studies showing declining antibiotic susceptibility of 
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clinical isolates derived from the cerebrospinal fluid of meningitis patients7. As an increasing number of infec-
tions are becoming harder or impossible to treat, there is an urgent need for the development of technologies that 
can complement or replace conventional antibiotics.
As a re-emerging technology, phage therapy holds great potential for the treatment of resistant and 
non-resistant bacterial infections, and promising results have been achieved in cases of compassionate use8. 
Virulent bacteriophages (or phages) propagate within a suitable host at the site of infection, ultimately lysing that 
host and repeating the cycle, allowing for the potential of single-dose administration to eradicate a large number 
of bacterial cells9. Phage therapy was reported to successfully treat meningitis caused by multiple pathogens as 
early as at the turn of the 21st century10,11 manifesting the ability of phages to cross physiological barriers, includ-
ing the BBB12, whereas many antimicrobials, including vancomycin, beta-lactams and other hydrophilic antibiot-
ics have reduced penetration across the BBB13. Studies performed in a rat meningitis model infected with E. coli 
O25b:H4-ST131, a strain producing extended-spectrum beta-lactamase CTx-M-15, showed 100% and 50% rat 
survival following administration of phage EC200PP 7 or 24 h post-infection respectively14.
A comprehensive understanding of phage interactions with human cells on a cellular and molecular level 
is desired to be able to accurately substantiate the efficacy of the approach. Phages are present on all body sur-
faces that are in direct contact with the exterior environment, including the skin, urogenital tract, oral cavity, 
gut and lungs15, in addition to the blood16. While their presence in body niches allows them to exert selective 
pressure on their bacterial hosts and hence to modulate the human microbiome, their presence in the blood 
allows for direct interaction with mammalian immune cells and the potential for induction of innate and adap-
tive immune responses17. Furthermore, the presence of phages in the blood might allow for direct contact with 
vascular endothelial cells with unknown biological consequences, yet the potential influence and significance of 
such interactions are yet to be explored.
We present a robust in vitro phage therapy model system of neonatal bacterial meningitis based on E. coli 
EV36, phage K1F and hCMECs allowing for a wide range of cellular and molecular analyses. We show that, in 
hCMEC cultures, phage K1F is phagocytosed and degraded by constitutive- and inducible PAMP-dependent 
LC3-assisted phagocytosis, does not initiate selective autophagy, and does not induce expression of inflammatory 
cytokines TNFα, IL-6, IL-8 or IFNβ. Conversely, E. coli EV36 is degraded by selective autophagy, and a potent 
inflammatory response is mounted towards the infection in the form of expression of inflammatory cytokines. 
Additionally, we show that phage K1F temporarily decrease the impedance of hCMEC cultures. This decrease in 
focal adhesion influences the endothelial barrier function by increasing the barrier permeability and this might 
represent a mechanism allowing for the transition of immune cells across the endothelial vessel.
Results
E. coli EV36 infects human cerebral microvascular endothelial cells in culture. Infection rates of 
hCMECs by E. coli EV36-RFP were determined by confocal microscopy and flow cytometry (Fig. 1).
The proportion of hCMECs containing intracellular bacteria, as quantified by confocal imaging, was increased 
in a concentration-dependent manner (Fig. 1A & Suppl. Figure 1). Estimates of infection rates in larger cell pop-
ulations were obtained by complementary approaches using flow cytometry (Fig. 1B–D). Full separation of RFP 
fluorescence signals from infected and non-infected cultures was achieved (Fig. 1B). The proportion of infected 
hCMECs increased in a concentration-dependent manner with increasing bacterial input (Fig. 1C). Additionally, 
a clear time-dependence of infection was observed in cultures infected at a single concentration (Fig. 1D).
The comparable results obtained by confocal imaging and flow cytometry demonstrated that both methods 
are applicable for quantifying E. coli infection of cultured hCMEC and that this infection is both concentration- 
and time-dependent.
Bacteriophage K1F host specificity. The host specificity of phages K1F and K1F-GFP towards K1 
capsule-expressing bacteria was confirmed by liquid culture growth assays (Fig. 2A,B).
The addition of phages caused the optical density of E. coli EV36 cultures to plateau and then to decrease, 
indicating successful infection (Fig. 2A), with phage K1F-GFP showing some delay in infection in comparison 
with phage K1F, whereas growth continued unhindered after addition of phage T7. In contrast, phages K1F and 
K1F-GFP were unable to infect E. coli MG1655 as no decrease in optical density was observed (Fig. 2B) whereas 
phage T7 successfully infected this strain. These data confirmed the high specificity of phages K1F and K1F-GFP 
towards E. coli strains such as EV36, which express the K1 capsule, and also suggest that GFP expression by phage 
K1F-GFP has some small fitness cost as it kills its host more slowly than phage K1F.
Effect of bacteriophage K1F on the viability and cell wall integrity of E. coli EV36. The effect of 
phage K1F infection on the viability and cell wall integrity of E. coli EV36 (Fig. 2C,D) was investigated using flow 
cytometry.
The addition of phage K1F decreased viability and cell wall integrity of E. coli EV36 cultures over time as indi-
cated by an increasing mean fluorescence intensity (MFI) of the membrane-impermeant nucleic acid dyes Sytox 
(Fig. 2C) and propidium iodide (PI) (Fig. 2D). The temporal differences observed between the two dyes are likely 
due to the properties and intensities of the dyes themselves. It is noteworthy that a decreasing rate of events was 
detected from 80 minutes onwards due to bacterial lysis, and that no events were detectable after 140 minutes, 
suggesting that no live bacteria were present.
Stability of phage K1F-GFP. The stability of phage K1F-GFP was further investigated using flow cytometry 
(Fig. 2E,F) and electron microscopy (EM) (Fig. 2G).
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Increasing GFP fluorescence was observed of E. coli EV36 cultures infected with phage K1F-GFP (Fig. 2F) 
over time. No events were recorded after 140 minutes incubation due to bacterial lysis. Two distinguishable pop-
ulations were observed when comparing the GFP-tagged phage at 0 h and 2 h (Fig. 2E).
Additionally, EM imaging showed that the gold-conjugated probe for GFP binds to phage K1F-GFP in a 
unique pattern (Fig. 2G); the phages are decorated with the probe in a ring-like shape surrounding the capsid, 
suggesting that there is enhanced binding of the probe to phage K1F-GFP in comparison with the controls, which 
showed no specific binding of the probe. This data confirmed the presence and high stability of the GFP fluoro-
phore located on the capsid of phage K1F-GFP.
Endotoxin concentration of phage preparations. The concentration of endotoxin, LPS, in phage 
preparations used to treat human cell cultures was determined using a Limulus Amebocyte Lysate assay. This 
was performed to ensure that the molecular and cellular changes observed was caused by phage interactions 
rather than bacterial remains. Supplementary Fig. 4 shows that phage added to cultures at 107 PFU/ml contained 
0.0060–0.086 EU/ml and cultures with phage added at 109 PFU/ml contained 0.60–1.3 EU/ml. Endotoxin con-
centrations in this range would enable intravenous administration of phage at a high titre while being well below 
the recommended 5 EU per kg of body weight per hour18. While the experimental concentration of endotoxins 
in this study is very low, the potential effect of trace bacterial contaminants is not accounted for. Therefore, inter-
pretation of data could be skewed by currently unknown effects of trace bacterial debris or interactions of these 
with phage particles.
Internalisation and degradation of bacteria and phages in human cerebral microvascular 
endothelial cells. The internalisation and degradation of phage K1F-GFP and E. coli EV36 in T24 human 
urinary epithelial cells has previously been studied in the context of in vitro phage therapy19. Here we expanded 
on this study using qualitative confocal microscopy and quantitative flow cytometry to examine the internaliza-
tion and processing of phage K1F in human cerebral microvascular endothelial cells (hCMECs).
Assessment of internalisation and degradation was initially performed as a co-localisation assay between bac-
teria or phage and phagosomal and lysosomal markers. hCMEC cultures were fixed and stained with antibod-
ies for either RAB7, a GTPase required for the normal progression of late endosomes to lysosomal fusion20,21 
(Fig. 3A–C), cathepsin-L, a cysteine protease important for lysosomal degradation of engulfed extracellular 
material22 (Fig. 3D–F), or LC3B, a microtubule-associated protein that is recruited by toll-like receptors for 
LC3-associated phagocytosis and autophagosome formation23 (Fig. 4A–C).
Figure 1. Infection by E. coli EV36-RFP of hCMEC cultures. (A) Representative fluorescent images showing E. 
coli EV36-RFP infection of hCMEC cultures at concentrations of 106 CFU/ml (left) and 107 CFU/ml (right). E. 
coli EV36-RFP fluorescence shown in red, DAPI in blue, and phalloidin in white (B) Flow cytometry histogram 
showing E. coli EV36-RFP infected hCMECs in red and non-infected hCMECs in grey, as detected by RFP 
fluorescence. (C,D) Mean percentages of E. coli EV36-RFP infected hCMECs (RFP-positive by flow cytometry) 
after a 1 h incubation period with concentrations of 103 to 107 CFU/ml (C), or 107 CFU/ml sampled over time 
(D); + /− SD, n = 3 in each case.
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Figure 2. Bacteriophage K1F infection of E. coli EV36. (A,B) Growth of E. coli EV36 (A) and E. coli MG1655 
(B) cultures infected by phages K1F, K1F-GFP or T7 at a MOI of 0.001 in comparison with uninfected control 
cultures, NTC (+/− SD, n > 3). (C–E) Analysis of bacterial cell death in phage-infected cultures by flow 
cytometry; E. coli EV36 cultures were infected with phage at a MOI of 0.001; NTC = uninfected control (C) 
Sytox Green Dead Cell Stain MFI (+/− SD, n = 3) of phage K1F infected E. coli EV36. (D) Propidium iodide 
(PI) MFI (+/− SD, n = 3) of phage K1F infected E. coli EV36. (E) Flow cytometry histogram of phage K1F-GFP 
infected E. coli EV36 at 0 min following infection (grey) or 120 min (green). (F) GFP MFI (+/− SD, n = 3) of 
phage K1F-GFP infected E. coli EV36; NTC = uninfected Control. (G) Negative staining EM images of sample 
(Gold-conjugated GFP binding probe with phage K1F-GFP) and controls. Wild-type control is represented 
by phage K1F incubated with the probe; Gold control was performed using only the 5 nm gold incubated with 
phage K1F-GFP.
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Co-localisation assays in hCMEC cultures showed that RAB7, cathepsin-L, and LC3B, all co-localise with E. 
coli EV36-RFP (Fig. 3A,D & 4A), phage K1F-GFP (Fig. 3B,E & 4B), or E. coli EV36-RFP and phage K1F-GFP in 
combination (Fig. 3C,F & 4C). RAB7 and cathepsin-L co-localisation suggested that E. coli EV36-RFP and phage 
K1F-GFP alike are internalised by constitutive phagocytosis and following a maturation process, these vesicles 
fuse with lysosomes. Constitutive phagocytosis is a continual process whereby the human cells sample the extra-
cellular space and uptake inert particles such as some nutrients24. Additionally, LC3B co-localisation suggests that 
components of the autophagy pathway are activated via inducible LC3-assisted phagocytosis25.
Figure 3. Lysosomal- and phagosomal markers of constitutive phagocytosis. (A–F) Immunofluorescent images 
showing hCMEC cultures fixed and stained with anti-RAB7 (A–C) and anti-Cathepsin-L (D–F) antibodies 
following a 1 h incubation with 107 CFU/ml E. coli EV36-RFP alone (A + D) or 107 PFU/ml phage K1F-GFP 
alone (B + E), or a 1 h incubation with 107 CFU/ml E. coli EV36-RFP followed by a 1 h incubation with 104 PFU/
ml phage K1F-GFP (C + F). DAPI stain is shown in blue and anti-RAB7/anti-Cathepsin-L antibodies in white. 
n = 3 in each case.
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Confocal microscopy image analysis also confirmed observations of previous studies performed in T24 
human urinary epithelial cells19, showing the ability of phage K1F-GFP to locate and infect E. coli EV36-RFP in a 
human cell environment and the formation of intracellular vacuoles containing phage-aggregates in human cells.
In addition, quantitative flow cytometry was used to measure the MFI of LysoTracker (Fig. 4D–F) and hLC3B 
(Fig. 4G,H). The LysoTracker is a pH-sensitive, membrane-permeable dye that labels acidic organelles with high 
selectivity26. The data showed a sharp increase over time of LysoTracker MFI of hCMEC cultures treated with E. 
coli (Fig. 4D), suggesting a shift in endosomal pathway activity towards an increased lysosomal activity, whilst 
Figure 4. Markers of LC3-assisted phagocytosis and lysosomal activity. (A–C) Immunofluorescent images 
showing hCMEC cultures fixed and stained with anti-LC3B antibody following a 1 h incubation with 107 CFU/
ml E. coli EV36-RFP alone (A) or 107 PFU/ml phage K1F-GFP alone (B), or a 1 h incubation with 107 CFU/
ml E. coli EV36-RFP followed by a 1 h incubation with 104 PFU/ml phage K1F-GFP (C). DAPI stain is shown 
in blue and anti-LC3B antibody in white. n = 3 in each case. (D,E) Analysis by flow cytometry. (D–F) Graphs 
showing LysoTracker MFI (+/− SD, n = 3) of hCMEC cultures incubated with 107 CFU/ml E. coli EV36 alone 
(D) or 107 PFU/ml phage K1F alone (E) over time, or in combination after 1 h incubation (F). (G,H) Graphs 
showing anti-hLC3B MFI (+/− SD, n = 3) of hCMEC cultures treated with 107 CFU/ml E. coli EV36 (G) or 107 
PFU/ml phage K1F (H) over time, or in combination after 1 h incubation (I). Probability values (p-values) are 
displayed as p ≤ 0.05 (*), p ≤ 0.01 (**), p ≤ 0.001 (***), p ≤ 0.0001 (****).
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hCMEC cultures treated with phage K1F showed a lesser gradual decrease (Fig. 4E). hCMEC cultures treated with 
E. coli EV36 and phage K1F in combination showed a small increase of LysoTracker MFI in comparison with cells 
treated with E. coli EV36 alone (Fig. 4F). This increased LysoTracker activity observed, is likely the result of an 
increase in bacterial debris, in the form of lipopolysaccharides (LPS), released by phage lysis.
Similarly, staining of hCMEC cultures stained with an hLC3B antibody showed a sharp increase over time 
following incubation with E. coli EV36 (Fig. 4G), while hCMEC cultures treated with phage K1F showed a lesser 
gradual decrease (Fig. 4H). hCMEC cultures treated with E. coli EV36 and phage K1F in combination (Fig. 4I) 
showed a small but significant decrease of hLC3B MFI in comparison with E. coli EV36 treatment alone. This 
observed decrease could translate to a quicker progression from phagosome maturation to lysosome degradation 
induced by the release of endotoxins following phage lysis.
Degradation of bacteria and phages by xenophagy. Alongside LC3-assisted phagocytosis, 
anti-bacterial selective autophagy (xenophagy) can occur when bacteria, internalised by phagocytosis, attempt 
to escape into the cytosol by rupturing the encapsulating membrane25. A further three antibodies were selected 
to distinguish between LC3-assisted phagocytosis and xenophagy: Galectin-8, a cytosolic lectin which monitors 
endosomal membrane integrity and responds to membrane damage by binding to exposed glycans27 (Fig. 5A–C), 
NDP52, a cargo-receptor that, when recruited by Galectin-8, initiates the formation of an autophagosome which 
triggers selective autophagy28 (Fig. 5D–F) and ubiquitin, the deposition of which on exposed cytosolic bacteria is 
sensed by a range of receptors, including NDP52, and ultimately restricting bacterial proliferation and initiating 
xenophagy29 (Fig. 6A–C).
Intracellular E. coli EV36-RFP in hCMEC cultures co-localised with antibodies for Galectin-8 (Fig. 5A), 
NDP52 (Fig. 5D) and ubiquitin (Fig. 6A), suggesting that E. coli EV36-RFP is capable of rupturing the phagoso-
mal membrane and initiating xenophagy. In contrast, image data showed no co-localisation between intracellular 
vacuoles containing phage K1F-GFP and either Galectin-8 (Fig. 5B), NDP52 (Fig. 5E), or ubiquitin (Fig. 6B), 
suggesting that phage K1F-GFP is solely degraded by constitutive- and LC3-assisted phagocytosis and does not 
initiate xenophagy. Additionally, hCMEC cultures infected with E. coli EV36-RFP and phage K1F-GFP in combi-
nation displayed identical co-localisation patterns to that of E. coli EV36-RFP infection alone, with co-localisation 
of both bacterial and phage signals with antibodies for Galectin-8 (Fig. 5C), NDP52 (Fig. 5F) and ubiquitin 
(Fig. 6C), indicative of xenophagy.
Additionally, flow cytometry was performed to quantify the ubiquitin-mediated contribution to degradation 
(Fig. 6D–F). hCMEC cultures incubated with E. coli EV36 showed an increase in ubiquitin MFI over time eventu-
ally reaching a plateau (Fig. 6D), while no difference was observed of hCMEC cultures incubated with phage K1F 
alone (Fig. 6E) or E. coli EV36 and phage K1F in combination (Fig. 6F). These data replicated the results obtained 
by imaging, suggesting that E. coli EV36 alone and not phage K1F, can initiate xenophagy.
Expression pattern of inflammatory markers of hCMEC cultures. The inflammatory response of 
human cerebral endothelial cells to E. coli EV36 and phage K1F individually and in combination was investigated 
by measuring the induction of inflammatory markers TNFα, IL-6, IL-8, IL-10 and IFNβ using real-time qPCR. 
hCMEC cultures treated with TNFα was included as a positive control for induction of expression (Fig. 7). TNFα 
is considered a master regulator of inflammation and is implicated in the pathogenesis of bacterial, viral, and 
chronic inflammatory disease. In response to TNFα, vascular endothelial cells will increase leucocyte adhesion 
and trans-endothelial migration illustrating its central role as a pro-inflammatory cytokine in clearing an infec-
tion30. While hCMEC cultures treated with phage K1F showed no change in the expression levels of TNFα over 
time (Fig. 7A), cultures treated with E. coli EV36 showed a significant and sharp increase (Fig. 7B). The TNFα 
expression induced by E. coli EV36 infection was reduced by approximately 50% with the addition of phage K1F 
(Fig. 7D). The onset of measurable TNFα induction occurs from 2 hours incubation with bacteria and beyond 
(Fig. 7B), which correlated with bacterial clearance (Fig. 2), suggesting that the measured expression at the 6-hour 
endpoint is independent of the presence of live bacteria.
During infections, IL-6, a pleiotropic cytokine involved in both acute and acquired immunity, and also in neu-
ral development and function, is rapidly produced to stimulate host defences such as induction of C-reactive pro-
tein expression, the concentration of which is directly related to the severity of infection31–33. Over time, hCMECs 
treated with phage K1F showed no statistically significant change in the expression levels of IL-6 (Fig. 7E), while 
cultures treated with E. coli EV36 (Fig. 7F) showed a gradual time-dependent increase. Control cultures treated 
with TNFα (Fig. 7G) showed a weaker response characterised by a gradual time-dependent increase through-
out the incubation period. Contrary to TNFα, IL-6 expression induced by E. coli EV36 treatment (Fig. 7H) was 
increased more than 200% with the addition of phage K1F, whilst no difference was observed between phage K1F 
incubation time points. This suggests that, in the context of phage therapy, the inflammation measured as the 
expression of IL-6 of hCMEC cultures is mainly induced by the influx of bacterial endotoxins released by phage 
lysis rather than the bacterial infection itself. TNFα and IL-6 are typically both induced by such a stimulus, often 
attributed to the action of NF-κB; however, the TNFα response to NF-κB is complex and negatively affected by 
the action of other cell type-specific factors that compete for its binding to the promoter34 which may explain the 
discordance in activation of TNFα and IL-6 in our experiments.
IL-8 is a potent chemokine involved in the inflammatory response, specifically attracting and activating neu-
trophils at the site of infection, and is associated with many chronic inflammatory conditions35. hCMEC cultures 
incubated with phage K1F showed no difference in IL-8 expression over time (Fig. 7I). E. coli EV36 treatment, on 
the contrary, induced a time-dependent increase of IL-8 expression of hCMEC cultures (Fig. 7J). A faster onset of 
increased IL-8 expression was observed in hCMEC cultures treated with TNFα (Fig. 7K). The induced expression 
of IL-8 following in vitro phage therapy of hCMEC cultures (Fig. 7L), was comparable to that of IL-6 expression, 
showing an average increase above 150% following phage K1F addition in relation to E. coli EV36 treated cultures 
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alone. No difference was observed between the three time points of phage K1F addition. As with IL-6 induction, 
the data suggests that the hCMECs respond in a higher degree to bacterial endotoxins released by bacterial clear-
ance following phage therapy that the actual bacterial infection itself.
The production of inflammatory cytokines in response to a stimulus is mediated mainly through new tran-
scription of cytokine genes36 and indeed levels of cytokine mRNA were close to zero in the absence of a stimulus. 
We confirmed mRNA induction by stimulus was reflected in protein levels for IL-6 as an exemplar, using ELISA 
(Fig. 7Q–T). For all conditions, there was a striking correlation between IL-6 protein levels over time and their 
respective mRNA expression profiles.
Figure 5. Markers of xenophagy. (A–F) Immunofluorescent images showing hCMEC cultures fixed and stained 
with anti-Galectin-8 (A–C) and anti-NDP52/CALCOCO2 (D–F) antibodies following a 1 h incubation with 107 
CFU/ml E. coli EV36-RFP alone (A + D) or 107 PFU/ml phage K1F-GFP alone (B + E), or a 1 h incubation with 
107 CFU/ml E. coli EV36-RFP followed by a 1 h incubation with 104 PFU/ml phage K1F-GFP (C + F). DAPI 
stain is shown in blue and anti-Galectin-8/anti-NDP52 antibodies in white. n = 3 in each case.
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The anti-inflammatory cytokine, IL-10, is known to play a role in limiting host immune responses towards 
pathogens37. In these experiments, the data showed no change in IL-10 expression over time following incubation 
with E. coli EV36 or phage K1F alone or in combination (Suppl. Figure 5).
IFNβ was included in these experiments to complement the broadly inflammatory cytokines already meas-
ured with a cytokine that has a known virus inducible expression. Expression of IFNs, including IFNβ, has been 
shown to be induced by activation of pattern recognition receptors in the early stages of viral infection38,39.
hCMEC cultures incubated with phage K1F showed no induced expression of IFNβ over time (Fig. 7M), how-
ever, cultures incubated with E. coli EV36 showed a small time-dependent increase of IFNβ expression (Fig. 7N). 
hCMEC cultures incubated with TNFα showed a barely significant induction of IFNβ (Fig. 7O). hCMEC cultures 
treated with both E. coli EV36 and phage K1F exhibited responses characterised by a greater variation within 
and between experiments of induced expression of IFNβ yielding no statistically significant differences between 
treatments. Collectively, the IFNβ data suggest that phage K1F does not induce inflammatory responses of IFNβ 
in hCMEC cultures and that the IFNβ expression induced by E. coli EV36 is more variable and smaller than the 
induced expression of TNFα, IL-6 and IL-8.
Temporal impedance profiles of hCMEC cultures. The temporal influence of E. coli EV36 and phage 
K1F alone and in combination on the barrier function of hCMEC cultures was determined using the xCELLi-
gence system (Fig. 8). The temporal impedance profile of hCMEC cultures treated with phage K1F showed a slow 
Figure 6. Ubiquitin targeted degradation. (A–C) Immunofluorescent images showing hCMEC cultures fixed 
and stained with anti-Ubiquitin antibody following a 1 h incubation with 107 CFU/ml E. coli EV36-RFP alone 
(A) or 107 PFU/ml phage K1F-GFP alone (B), or a 1 h incubation with 107 CFU/ml E. coli EV36-RFP followed 
by a 1 h incubation with 104 PFU/ml phage K1F-GFP (C). DAPI stain is shown in blue and anti-Ubiquitin 
antibody in white. n = 3 in each case. (D–F) Graphs showing anti-Ubiquitin MFI (+/− SD, n = 3) obtained by 
flow cytometry of hCMEC cultures incubated with 107 CFU/ml E. coli EV36 alone (D) or 107 PFU/ml phage 
K1F alone (E) over time, or in combination after 1 h incubation (F). Probability values (p-values) are displayed 
as p ≤ 0.05 (*), p ≤ 0.01 (**), p ≤ 0.001 (***), p ≤ 0.0001 (****).
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divergence between NTC and phage K1F treated cultures at the highest concentrations of 107 and 109 PFU with 
detectable signal after approx. 12 hours incubation (Fig. 8B). The decrease in impedance due to phage K1F was 
sustained long-term (Fig. 8A), and reached maximum levels after approx. 35 hours incubation; a reduced response 
was detected by around 72-hour of incubation. To assess if these observations were specific to phage K1F, a 
similar experiment was performed using phage T7. This experiment showed a similar concentration-dependent 
decrease (Suppl. Figure 2), suggesting that these observations could be relevant to responses to phage in general. 
Figure 7. Expression pattern of inflammatory markers by real-time qPCR (A–P). hCMEC cultures were 
incubated with 107 CFU/ml E. coli EV36, 107 PFU/ml phage K1F or 500 pg/ml TNFα and specific mRNA levels 
measured over time, or incubated with 107 CFU/ml E. coli EV36 having 104 PFU/ml phage K1F added 1 h 
before-, simultaneously-, or 1 h after bacterial addition, and incubated for 6 h before RNA harvest. Real-time 
qPCR was performed with primer pairs specific for TNFα (A–D), IL-6 (E–H), IL-8 (I–L) and IFNβ (M–P). 
Data were expressed relative to internal control (GAPDH) and then normalised to the untreated control value. 
Expression of IL-6 protein as measured by ELISA (Q-T). hCMEC cultures were incubated with 107 PFU/ml 
phage K1F, 107 CFU/ml E. coli EV36 or 500 pg/ml TNFα, or incubated with 107 CFU/ml E. coli EV36 having 
104 PFU/ml phage K1F added 1 h before-, simultaneously-, or 1 h after bacterial addition, and incubated for 6 h. 
NTC = Untreated cultures. +/− SD, n = 3 in each case. Probability values (p-values) are displayed as p ≤ 0.05 
(*), p ≤ 0.01 (**), p ≤ 0.001 (***), p ≤ 0.0001 (****) and not statistically significant p ≥ 0.05 (ns). P-values 
are relative to NTC for single treatments experiments and relative to E. coli EV36 for combination treatment 
experiments.
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Additionally, as the impedance measurement is affected not only by cell-to-electrode adhesion but also cell pro-
liferation, a control experiment was performed measuring the proliferation of hCMEC cultures treated with 
phage K1F or T7 at identical concentrations. This experiment showed no difference in cell proliferation over time 
between NTC and cultures treated with phages (Suppl. Figure 3), suggesting that the proliferation of hCMEC 
cultures is not influenced by phage addition.
The impedance of hCMEC cultures treated with E. coli EV36 showed an immediate and dramatic decrease 
over the initial 10 hours for all concentrations (Fig. 8D). The detrimental effect of E. coli EV36 infection on the 
hCMEC cultures is clear with no recovery during the experiment (Fig. 8C), ending at a decrease of >95% across 
all bacterial concentrations.
In modelling several in vitro phage therapy intervention protocols, phage K1F was added to hCMEC cultures 
1 hour before, simultaneously, and 1 hour after the addition of E. coli EV36 (Fig. 8E,F). The immediate and dra-
matic influence of bacterial infection is similar to experiments without phage addition, however, the addition 
of phage K1F 1 hour prior to or simultaneously with E. coli EV36 addition, allowed the impedance of hCMEC 
cultures to transiently recover (Fig. 8F) in the initial hours of infection. Ultimately, however, despite phage inter-
vention, the impedance was not recovered beyond the initial 10 hours of incubation and similar effects with a 
decrease of >95% across all treatments were observed.
Discussion
In this study, we have aimed to develop an in vitro phage therapy model for studying bacterial neonatal meningi-
tis. As part of this process, we initially infected hCMEC cultures with E. coli EV36. We present that the infection 
rate of hCMEC cultures is time and concentration-dependent. The percentage of individual hCMECs contain-
ing intracellular bacteria was quantified by microscopy and flow cytometry. The two methods of quantification 
yielded very similar time and concentration-dependent results validating their application. hCMEC cultures incu-
bated with 107 CFU E. coli EV36-RFP for 1 h showed infection rates of approx. 50%. This is considerably higher 
than the infection rate previously obtained of approx. 20% in human urinary bladder epithelial cells (T24)19. This 
highlighted inherent tissue-specific properties and the necessity for unique tissue-specific model systems to study 
the mechanism of bacterial infection and phage intervention. We further tested the bacteriophage K1F which we 
found to display high host specificity towards E. coli EV36. The specificity of phage K1F against its bacterial host 
E. coli EV36 was confirmed in liquid cultures, where phages K1F and K1F-GFP were shown to lyse E. coli EV36 
cultures and not E. coli MG1655. Conversely, Phage T7 was shown to lyse E. coli MG1655 and not E. coli EV36. 
This demonstrates the high host specificity of the phages used in this study. Infection dynamics assessed by flow 
cytometry in the form of bacterial viability and cell wall integrity by Sytox40 and Propidium Iodide (PI)41 staining 
respectively, showed a population Mean Fluorescence Intensity (MFI) increase of over time of both Sytox and PI 
culminating immediately before bacterial clearance. It is notable that both stains are membrane-impermeable 
and thus the fluorescent signal is only present in the brief interval from initial lysing to complete dismantlement 
of the bacterial membrane.
Figure 8. Temporal impedance profiling as measured using the xCELLigence system (A–F). Graphs displaying 
the barrier resistance over time of hCMEC cultures treated with phage K1F at a concentration range of 105 to 
109 PFU/ml (A,B), E. coli EV36 at a concentration range of 103 to 107 CFU/ml (C,D), or combination treatment 
of 107 CFU/ml E. coli and 104 PFU/ml phage K1F added 1 h before-, simultaneously-, or 1 h after bacterial 
addition (E,F). NTC = Untreated hCMEC cultures. X-axis show time from cell seeding. Vertical lines denote the 
addition of treatment at 0 h, and 24- and 72 h post treatment. The data is presented as the average normalised 
cell index across the acute (24 hours) and long-term (72 hours) incubate period (+/− SD, n > 3).
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The ability and efficiency of phage K1F-GFP to locate and infect intracellular E. coli EV36 in a human cell 
environment has been confirmed in previous studies19, however, the signal stability of GFP is often a point for 
discussion. We therefore initially assessed the fluorescent signal emitted by phage K1F-GFP during infection in 
E. coli EV36 using flow cytometry. We show that bacterial cultures infected with phage K1F-GFP for two hours 
have a distinctly different fluorescent profile than non-infected bacterial cultures. The fluorescence emitted was 
time-dependent with a continual increase until bacterial clearance. The location of individual GFP molecules was 
confirmed by electron microscopy, showing the unequivocal presence of individual GFP molecules across the 
capsid in alignment with the engineering design of bacteriophage K1F-GFP which places it on the minor capsid 
protein. These results are in accordance with a previous study42, which demonstrated that the gp10b minor capsid 
protein is present in a limited number of copies, around 15 copies per capsid, in comparison with the major gp10a 
protein, which forms most of the capsid and is expressed in around 429 copies.
In support of previous results obtained in urinary epithelial cells (T24)19, our initial imaging data show that 
E. coli EV36 and phage K1F individually and in combination co-localise with antibodies for RAB7, Cathepsin-L 
and LC3B in hCMEC cultures. The protein targets of these antibodies are involved in phagosome maturation20,21, 
lysosomal degradation22 and autophagosome formation23 respectively. Collectively, this illustrates a path of inter-
nalisation and degradation of phage K1F by constitutive phagocytosis succeeded by lysosomal degradation along 
the pathway of LC3-assisted phagocytosis.
LC3-assisted phagocytosis is dependent on the recognition of Pathogen Associated Molecular Patterns 
(PAMPs) by Toll-like Receptors (TLRs)43, suggesting that mammalian cells recognise phages via TLRs in order 
to degrade via them via this pathway. Multiple intracellular TLRs are able to recognise viral nucleic acids, specifi-
cally, TLR3 recognises dsRNA, TLR7 and TLR8 recognises ssRNA and TLR9 recognises DNA44.
The concentration of acidic organelles, including lysosomes, as measured by LysoTracker, decreases over time 
following phage K1F invasion in hCMEC cultures. It is feasible that the accessible pool of lysosomes is being 
exhausted during phage degradation, while the cells are not immediately replenishing this store. This is seen in 
sharp contrast to the substantial increase of lysosome concentration following E. coli EV36 infection in hCMEC 
cultures. Interestingly, phage addition to E. coli EV36 infected hCMECs increases the lysosomal activation addi-
tionally. This is likely linked to the increase in bacterial debris following bacterial lysis, as the presence of LPS 
from gram-negative bacteria is a known inducer of autophagy45 leading to increased lysosome activity.
While we show that phage K1F and E. coli EV36 are degraded by constitutive and LC3-assisted phagocytosis in 
hCMEC cultures, it is evident that E. coli strains can transit from the phagosome into the cytosol in an attempt to 
evade the innate immune response of lysosomal degradation25,46. In line with previous observations in T24 cells19, 
our imaging efforts show that E. coli EV36 and not phage K1F co-localise with antibodies for Galectin-8, NDP52 
and Ubiquitin in hCMEC cultures. These antibodies target proteins involved in the initiation- and progression of 
xenophagy, which is pathogen-selective autophagy25,47. Specifically, breaches to the phagosomal membrane are 
sensed by cytosolic Galectin-8 which binds to exposed membrane-bound glycans27 and interacts with cytosolic 
NDP52 to mediate autophagosome formation28 thus triggering selective autophagy. Ubiquitination of the escaped 
bacterium47 and the Galectin-8-NDP52 complex25 further promote pathogen degradation. This finding is sub-
stantiated by quantitative flow cytometry data showing an increase of ubiquitin abundance over time in hCMEC 
cultures infected with E. coli EV36, whereas hCMEC cultures invaded with phage K1F show no difference of 
ubiquitin abundance over time.
Real-time qPCR analysis demonstrated that phage K1F does not induce the expression of inflammatory 
cytokines TNFα, IL-6, IL-8 or IFNβ by hCMEC cultures. In contrast, phage upregulation of TNFα and IL-6 
expression has been observed in vitro in peripheral blood monocytes (PBMCs)48. The inflammatory response 
of PBMCs conforms to the nature of this collection of immune cells, whereas the absence of an inflammatory 
response of hCMEC cultures is compatible with the nature and function of the endothelium49 despite their 
known involvement in immune processes50. Expression of Type I interferons, including IFNβ, can be induced 
by nucleic acid-recognising TLRs44 and PAMPs such as LPS. While this study found phages were degraded, in 
part, by PAMP-recognition dependent LC3-assisted phagocytosis, no increase was observed in IFNβ expression 
of hCMEC cultures following phage invasion. Further studies would be required to investigate which TLR(s) is 
associated with phage degradation via the LC3-assisted phagocytic pathway. The absence of induction of inflam-
matory cytokines by phage K1F is seen in sharp contrast to the substantial upregulation of expression induced 
by E. coli EV36 in particular TNFα, IL-6 and IL-8. This is in line with previously published bacterial infection 
patterns of the human endothelium51. Interestingly, in vitro phage therapy using bacteriophage K1F against E. 
coli EV36 infection of hCMEC cultures resulted in a reduction in TNFα expression of approximately 50% com-
pared to bacterial infection alone. As a central pro-inflammatory cytokine in bacterial infection30, the reduction 
observed in TNFα expression is likely related directly to the reduction in bacterial concentration as a result of 
phage intervention.
Conversely, a steep increase was observed following in vitro phage therapy in the expression of IL-6 and 
IL-8. The outcome of phage intervention is bacterial lysis and a high concentration of bacterial debris, LPS. This 
increase in cytokine expression correlates well with results showing LPS induction of IL-6 and IL-8 expression in 
lymphatic microvascular cells (LECs)52.
Finally, we present that bacteriophage K1F decreases the barrier function of hCMEC cultures.
hCMEC cultures incubated with phage K1F at concentrations of approximately 107 PFU/ml and above showed 
a temporal reduction of impedance over a considerable length of time.
As far as we are aware this is the first time this has been reported. Similar temporal profiles were observed 
for incubation with phage T7. Further control experiments showed that these observations were unrelated to 
hCMEC proliferation.
The frequency of 10 kHz used in these experiments principally favours the measurement of cellular focal 
adhesion53. The cellular change indicated by a decrease in impedance is weaker focal adhesion to the extracellular 
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matrix, suggesting that the endothelial barrier function is decreased and thus the endothelium is becoming more 
permeable in the presence of high concentrations of phage. Circulating free phage is rapidly degraded once the 
host bacteria have been cleared in in vivo9,14 and in vitro54 tests of phage intervention, which suggests that the 
recovery of hCMEC impedance observed here following prolonged incubation was directly linked to a reduction 
in bacteriophage concentration. E. coli EV36 infection in hCMEC cultures resulted in a rapid and total reduction 
in barrier resistance in line with previous in vivo55 and in vitro56 studies of endothelial barrier function during 
infection. Interestingly, phage intervention only conferred a short-lived recovery of barrier resistance, ultimately 
leaving the hCMEC culture to perish due to increasing concentration of LPS.
Continual stimulation of antiviral immune responses by commensal bacteriophage activation of innate 
immune pathways has been shown to induce low-level cytokine production, resulting in continuously activated 
immune cells that confer protection against pathogenic viral infections17,57. Additionally, a non-host-derived layer 
of immunity is theorised to result from phages residing in mucosal layers (BAM model), whereby the presence of 
phages at the site-of-entry for pathogenic bacteria confers immunity as well as impacting the mucosal-resident 
community of commensal bacteria58. We hypothesise that modulation of endothelial adhesion could be added 
to the list as an inflammatory mechanism supporting the delivery and extravasation of immune cells to a site of 
infection.
Overall, the model we propose here to study the interaction between K1F phage, its host bacteria and hCMEC 
human cells, even though it is in initial steps in terms of directly approaching a clinical phage therapy interven-
tion, can give us useful information to be used when phage therapy is considered. Based on our results, K1F phage 
is safe to be used as it does not increase inflammation in hCMEC cells and targets successfully its host Escherichia 
coli K1. More studies are required to provide further proof that the current model can be linked even more accu-
rately with real phage therapy examples of neonatal meningitis.
Conclusion
Collectively, the presented results expand the growing understanding of interactions between phages and human 
cells, reinforce the existing knowledge of phage internalisation and degradation, complemented by an analysis of 
expression patterns of inflammatory cytokines during in vitro phage therapy and results showing the temporal 
influence of phages on the barrier permeability of human endothelial cells. While there is evidence of interactions 
between bacteriophage and human cells, it is clear that the responses mounted by the human cells are not inflam-
matory or defensive. The contribution of this study is valuable in the continued development of phage therapy for 
bacterial neonatal meningitis and the ongoing war against antibiotic-resistant bacterial infections.
Materials and Methods
Human cell culture. The blood-brain barrier hCMEC/D359 (human cerebral microvascular endothelial 
cells) cell line (Merck, UK) consists of enriched cerebral microvascular endothelial cells immortalised by len-
tiviral vector transduction with the catalytic subunit of human telomerase (hTERT) and SV40 large T antigen.
hCMECs were cultured in EndoGRO-MV Complete Media (Merck) supplemented with 1 ng/ml bFGF (FGF-
2) (Merck), 100 IU/ml Penicillin (Sigma-Aldrich), and 100 μg/ml Streptomycin (Sigma-Aldrich) and maintained 
under a humidified atmosphere at 37 C in 5% CO2. All culture vessels were coated with 5 μg/cm2 Collagen Type 1 
(Collagen-1) (Merck) in PBS for 1 h at 37 C before use.
Preparation of hCMEC cultures for experiments. For immunocytochemical (ICC) imaging, flow 
cytometry and real-time qPCR hCMECs were seeded onto 6-well plates in culture medium and allowed 48 h to 
settle. The seeding density for ICC imaging was approx. 2.1 × 104 cells/cm2, and approx. 5.2 × 104 cells/cm2 for 
flow cytometry and real-time qPCR.
Prior to an experiment, the culture medium was replaced with Leibovitz L-15 media (Lonza), a medium 
designed to support cell growth in environments lacking CO2 equilibration, and the cultures were moved to a 
37 C incubator suitable for bacterial infections.
Growth determination of hCMEC cultures. hCMEC cells were seeded in culture medium onto 96-well 
tissue culture plates at a density of approx. 1.5 × 104 cells/cm2 and allowed 24 hours to settle. Phages T7 or K1F 
were added to corresponding wells with untreated cells included as a control. The cell density was determined 
at the time of seeding and at subsequent sampling points by manually using a haemocytometer on a trypsinised 
population.
Bacterial culture. Three bacterial strains were used in this study: 1) E. coli EV36, a K12/K1 hybrid deriva-
tive60, was kindly provided by Drs Eric R. Vimr and Susan M. Steenbergen. This hybrid strain allowed for work 
to be performed in a biohazard level 1 laboratory while retaining the phenotypic properties of a pathogenic K1 
strain. 2) E. coli EV36-RFP, an EV36 derivative constructed by electroporation with low-copy plasmid pSB6A1 
constitutively expressing the mRFP1 protein and cultured under 100 μg/ml ampicillin selection. 3) E. coli 
MG1655 (ATCC 47076) (LGC Standards, UK), a well-documented K12 strain, that was included as a control for 
phage selectivity.
Bacteriophage propagation and purification. Three phage strains were used in this study: 1) Phage 
K1F, a well-characterised strain that shows high specificity towards K1-capsule expressing bacteria61, was kindly 
provided by Dr Dean Scholl. The K1 polysaccharide capsule of E. coli is recognised and degraded by a phage 
K1F-encoded endosialidase allowing phage infection6. 2) Phage K1F-GFP, a phage K1F derivative engineered 
by genome integration of GFP as previously described19. 3) Phage T762, an extensively used strain showing high 
specificity towards commensal E. coli K12 strains.
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Single-clone phage preparations were obtained from cleared bacterial cultures following a modified 
Castro-Mejia et al.63 protocol previously published19. Briefly, this comprised the release of phage particles from 
bacterial membranes by NaCl addition, phage precipitation by PEG8000 addition, followed by CsCl gradient 
column separation, and size exclusion by dialysis. The concentration of endotoxins (LPS) in purified phage prepa-
rations were determined using the Limulus Amebocyte Lysate (LAL) Chromogenic Endpoint Assay (Hycult 
Biotech) following the manufacturer’s protocol. Endotoxin concentrations in phage preparations, media and dil-
uents used in this study are presented in Suppl. Figure 4.
Phage host selectivity was assessed by phage infection of liquid bacterial cultures. Phages K1F, K1F-GFP or T7 
were added to E. coli EV36 or E. coli MG1655 in a 96-well plate and the optical density at 600 nm was measured 
using FLUOstar Omega (BMG Labtech). Uninfected cultures and LB alone were included as controls.
Flow cytometry analysis of phage infection in bacteria. Log-phase E. coli EV36 cultures were stained 
with 2 μM final concentration propidium iodide (PI) (Invitrogen) or 3 μM final concentration Sytox Green Dead 
Cell Stain (Invitrogen), and incubated for 20 min before the addition of phage K1F.
Assessment of fluorophore stability was performed by the addition of phage K1F-GFP alone to a separate 
bacterial culture.
Data acquisition and analysis were performed using the LSR Fortessa flow cytometer and FACSDiva software 
(BD Biosciences). Bacterial populations were initially gated on size via SSC/FCA to exclude cellular debris. 10,000 
events were detected of each population. The mean fluorescent intensity (MFI) was detected for gated bacterial 
populations using B488-530/30 A optics for Sytox Green and phage K1F-GFP detection, and YG561-586/15 for 
propidium iodide detection.
Electron microscopy of phage K1F-GFP. The probe was generated using 5 nm gold functionalized with 
maleimide groups (Sigma-Aldrich) conjugated to a GFP binding nanobody which has been proven to bind with 
a high efficiency to GFP proteins64, while similar approaches of nanobodies conjugated to gold have shown to 
be able to track GFP proteins in cells65. This approach allows tracking of the GFP protein present on the gp10b 
capsid protein, as the nanobody binds to the GFP and the gold allows visualization with EM. For the binding of 
the probe to phage K1F-GFP, 2 µL of 108 PFU/ml phage was incubated with 1 µL of the probe (1.8 × 10−6 mol/L 
concentration) at room temperature for 1 hr. Following this, 5 µL of 1% PBS was added and the total volume was 
incubated on a formvar/carbon-coated grid (EMResolutions) that was previously glow discharged for 1 min. After 
10 minutes, the grid was washed 3 times with 1% PBS, followed by 4 minutes incubation with 2% uranyl acetate 
staining. The grid was imaged using a Jeol 2100Plus TEM microscope fitted with a Gatan OneView IS camera 
at 200 kV. Gold controls and wild-type controls were generated using the same protocol, with phage K1F-GFP 
incubated with only 5 nm gold functionalized with maleimide groups or phage K1F incubated with the probe, 
respectively. The acquired images were then processed using Fiji (imageJ) software.
Immunofluorescent confocal microscopy. hCMEC cultures were fixed in 4% paraformaldehyde 
(ThermoFisher Scientific) for 15 min, permeabilised in ice-cold PEM buffer (80 mM PIPES pH 6.75, 5 mM EGTA, 
1 mM MgCl2) with 0.05% (v/v) Saponin for 5 min, and quenched with 50 mM NH4Cl in PBS for 15 min. PBS 
washes were performed after each step.
For association assays, the fixed cells were stained with the following primary antibodies diluted in 0.05% 
Saponin in PBS for 60 min at room temperature, as described also previously19: 40 μg/ml anti-RAB7 (Bioss Inc, 
MA); 1 μg/ml anti-Cathepsin L (Abcam); 5 μg/ml anti-LC3B (Sigma-Aldrich); 1 μg/ml anti-CALCOCO2/NDP52 
(Abcam); 1 μg/ml anti-Galectin-8 (R&D Systems); or 1 μg/ml anti-mono- and polyubiquitinylated conjugated 
monoclonal antibody (FK2) (Enzo Life Sciences). This was followed by detection with secondary antibodies by 
incubation for 45 min at room temperature with Cy5 Affinipure Donkey Anti-goat, Anti-rabbit or Anti-mouse 
IgG (Jackson ImmunoResearch, PA). The signal from GFP tagged phage was further enhanced with 5 μg/ml 
GFP-Booster (Chromotek, Germany) during incubation with secondary antibodies. For invasion assays, the fixed 
cells were stained only with 5 μg/ml Phalloidin CF680R Conjugate (Biotium) for 40 min.
Stained coverslips were mounted on microscope slides using DAPI-containing Fluoroshield Mounting 
Medium (Abcam, UK) and secured with CoverGrip Coverslip Sealent (Biotium). Finally, the cells were imaged 
using a Zeiss LSM880 confocal microscope with Airyscan, using the following excitation wavelengths: DAPI at 
405 nm, GFP at 561 nm, RFP at 561 nm and far-red (Cy5) at 633 nm.
Flow cytometry analysis of infection in human cells. Sampling was performed by aspirating spent 
media, trypsinising and centrifuging each the suspension. MEDIUM A (Fix & Perm Cell Permeabilization Kit) 
(Life Technologies) was added to the pellet and incubated according to the manufacturer’s instructions. The cell 
suspension was diluted in eBioscience Flow Cytometry Staining Buffer (Invitrogen) and pelleted by centrifuga-
tion. MEDIUM B (Fix & Perm Cell Permeabilization Kit) (Life Technologies) containing either 1/100 dilution 
anti-hLC3B Alexa Fluor 647 Conjugated Ab (R&D Systems), or 1 ug/ml Anti-mono- and polyubiquitinylated 
conjugated monoclonal antibody (FK2) (Enzo Life Sciences), was added to the sample and incubated for 45 min-
utes. Following incubation, the cell suspension was diluted in Staining Buffer and pelleted by centrifugation as 
above. For ubiquitin staining only, a secondary incubation with MEDIUM B containing 2 ug/ml Goat anti-mouse 
IgG (H + L) Cross Absorbed Secondary Ab Alexa Fluor 647 (Invitrogen) was performed for 30 minutes. Finally, 
the cell suspension was resuspended in Staining Buffer and placed on ice until acquisition.
MEDIUM A and MEDIUM B were not supplemented with antibodies for LysoTracker (Invitrogen, UK) stain-
ing. LysoTracker was added to samples 30 minutes prior to trypsinisation at a final concentration of 500 nM. The 
endocytic pathway follows a pH gradient ranging from ~6.3 in early endosomes, ~5.5 in late endosomes, to ~4.6 
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in lysosomes66. An observed increase of LysoTracker MFI indicates a downstream shift in endosomal pathway 
activity towards increased lysosomal activity.
hCMECs treated with E. coli EV36-RFP alone were analysed both fixed and live. For fixed cells, the Fix & Perm 
Cell Permeabilization Kit was used as above. For live cells, the trypsinised cells were diluted in PBS and Sphero 
Beads AccuCount Fluorescent Particles (SpheroTech, IL) were added according to the manufacturer’s instruc-
tions, and data acquired immediately thereafter.
Acquisition and analysis were performed using the LSR Fortessa flow cytometer and FACSDiva software (BD 
Biosciences). 10,000 events were detected of each population. The hCMEC populations were initially gated on 
size via SSC/FCA, excluding cellular debris and planktonic bacteria. The mean fluorescent intensity (MFI) was 
detected for gated hCMEC populations using the following optics: R640-670/14-A for LysoTracker and Alexa 
Fluor 647 conjugated Abs, and YG561-586/15 for E. coli EV36-RFP.
Quantitative real-time PCR. hCMEC cultures were incubated with E. coli EV36, phage K1F or TNFα 
(Sino Biological, China) in biological triplicates. RNA was recovered using the GenElute Mammalian Total 
RNA Miniprep Kit (Sigma-Aldrich) with DNase I Digestion Kit (Sigma-Aldrich) following the manufacturer’s 
protocol.
1 μg RNA samples were used for cDNA synthesis using 100 U Superscript III (Invitrogen) primed by 50 nM 
Random Hexamers (Invitrogen) and 10 μM dNTP Mix (Thermo Scientific).
Real-time PCR of cDNA samples was performed with Brilliant III SYBR Green qPCR Master Mix with 
Low ROX (Agilent) using the Stratagene Mx3005P instrument with MxPro v4.10 build 389 software (Agilent 
Technologies). Each sample was quantified in technical triplicate using primer sets for GAPDH67, TNFα68, IL-669, 
IL-870, IL-1071 and IFNβ72.
Data analysis was performed using the Comparative Ct Method73. ΔCt values for TNFα, IL-6, IL-8, IL-10 and 
IFNβ were calculated by subtracting the average GAPDH Ct value from the average Ct value obtained for each 
gene. ΔΔCt values were calculated by subtracting ΔCt values of untreated cultures from ΔCt values of treated 
cultures. The fold change was calculated by taking the log base 2 of ΔΔCt values.
Detection of IL-6 protein expression using ELISA. hCMEC cultures were incubated with E. coli EV36, 
phage K1F or TNFα (Sino Biological, China) in biological triplicates. Spent media was recovered, centrifuged, 
sterile filtered and stored at −80C until analysis. Expression of IL-6 protein was detected using the Human IL-6 
Uncoated ELISA kit (Invitrogen) following the manufacturer’s instructions.
Temporal impedance measurements of human cells. hCMECs were seeded into Collagen-1 coated 
E-Plate VIEW 16 PET (ACEA Biosciences) at a concentration of 5 × 104 cells/well in assay media. The plates were 
then inserted into the RTCA DP station and the cells allowed approx. 24 h to settle before the addition of bacteria 
or phage. The acquisition was performed using the xCELLigence RTCA DP instrument (ACEA Biosciences) 
housed in a humidified incubator at 37 C with 5% CO2. The instrument was set to a single frequency of 10 kHz 
with 5 min measuring intervals over the course of 96 h. Using a fixed frequency of 10 kHz, the current predom-
inantly travels paracellularly allowing for impedance measurements relating to the cell-to-electrode adhesion 
(focal adhesion) of the cells53. The parameter measured by the xCELLigence system, the Cell Index, represents 
the relative changes in frequency-dependent electrode resistance or impedance. Changes observed in impedance 
of confluent endothelial cells reflect changes in barrier function74. The Cell Index was normalised to 1 relative to 
approx. 1 h before the addition of treatments.
Quantification and statistical analysis. All quantification and statistical analysis were performed using 
GraphPad Prism 8.2.1 (San Diego, CA). Probability values for flow cytometry- and qPCR datasets were calculated 
using the unpaired t-test assuming Gaussian distribution. Level of significance is presented in relevant graphs.
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